Quick answer
EHL Bio publishes its patent and research list to demonstrate technical capability, spanning a fat harvesting/SVF separation kit, 15-PGDH inhibitor applications for atopic dermatitis and rheumatoid arthritis, and a three-dimensional low-oxygen culture method for producing conditioned media. The key distinction for readers: a patent protects an invention; it does not mean the product's efficacy is proven or that it is approved for treatment.
The patents filed and granted
Listed patents include a novel thiazolidinedione derivative (filed 2012) that inhibits 15-PGDH, relevant to cardiovascular, gastrointestinal and renal disease and hair loss prevention; a fat harvesting and SVF separation kit (2016); a cosmetic composition from stem cell conditioned media and its production method (2018); and 15-PGDH inhibitor patents for atopic dermatitis and rheumatoid arthritis.
The development ladder for a cell drug
The cell drug pathway runs candidate → preclinical → phase 1 (safety) → phase 2 (dose and efficacy signal) → phase 3 (confirmatory efficacy) → registration. EHL's most advanced asset, ADSTEM, sits at phase 2.
Key regulatory milestones
Regulatory milestones the company cites include Japanese CPC certification in 2017, Korea's first human cell handling licence, and being the country's first certified cell processing facility.
How to read research claims without being misled
Practical advice: when an advert cites patents or research counts, ask what stage the product you would actually receive is at, how many humans have been studied, and what its legal status is in the country where you would be treated.
Last updated: 2026-08-28 · This content is for information only and is not medical advice. Consult a qualified doctor before making treatment decisions.